Biotech Startups

Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds. Its pipeline includes a Phase 2-ready asset and multiple preclinical programs targeting brain health and neuroplasticity.

12 investors

Future Fields uses fruit flies as bioreactors to produce difficult-to-express proteins at scale for pharmaceutical, agricultural, and food applications. The company aims to enable the development of novel biological products across healthcare, agriculture, and nutrition sectors.

12 investors

HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients. The company markets its technology to healthcare providers internationally.

12 investors

Medable provides a cloud-based platform for clinical research that uses AI and digital tools to accelerate the development of therapies by improving the quality, reach, and efficiency of clinical trials. The platform serves pharmaceutical sponsors, contract research organizations (CROs), and clinical research sites.

12 investors

Medra builds robotic systems integrated with AI, computer vision, and natural language processing to automate data collection for life science research. The company serves biotech and academic research labs seeking high-precision, large-scale experimental data collection.

12 investors

Mindstate Design Labs is a clinical-stage drug development company that uses AI to map the biological basis of emotion and cognition, synthesizing psychedelic phenomenology and biochemical data to design pharmaceutical compounds that induce specific therapeutic emotional and cognitive states for mental health treatment.

12 investors

Mosa Meat is a company developing cultivated meat. This page is an investment inquiry form for parties interested in investing in the company.

12 investors

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation. Its pipeline focuses on autoimmune and inflammatory diseases with large patient populations and unmet medical need.

12 investors

Pivot Bio develops agricultural innovations focused on transforming farming practices through microbiology and genetics. The company serves farmers worldwide.

12 investors

Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).

12 investors

Redcliffe Labs is a diagnostic services company offering doctor-curated health checkup packages, genetic and pathology testing, along with expert consultation, AI assistance, and personalized health guidance. It serves patients across India with accessible, affordable diagnostics, including a women-centric platform.

12 investors

Sana is a biotech company developing engineered cell medicines, including gene therapies for gene modification and delivery, cell replacement therapies using stem cell biology, and manufacturing solutions to improve patient access to these treatments.

12 investors

Synthego develops CRISPR gene-editing and molecular diagnostics products, including custom CRISPR editors in mRNA or protein formats, base editors, and cell-free protein and RNA production systems. It serves researchers and cell and gene therapy developers in the biotechnology industry.

12 investors

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease. It operates as a clinical-stage biopharmaceutical company advancing small molecules, antibodies, and related drug programs in oncology and fibrotic diseases.

11 investors

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development. The company serves patients with cancer through novel drug candidates advancing in clinical trials.

11 investors

Develops alternative textile materials to replace polyester and reduce the fashion industry's plastic consumption and carbon emissions.

11 investors

Arcus Biosciences is a clinical-stage biopharmaceutical company that designs small molecule and monoclonal antibody combination therapies for people with cancer. Founded in 2015, it runs an in-house discovery and development organization spanning research through commercialization for oncology patients.

11 investors

Aspect Biosystems develops bioprinted tissue therapeutics using a platform that combines AI-powered bioprinting, computational design tools, therapeutic cells, and biomaterials to create implantable allogeneic tissues. Its pipeline targets metabolic and endocrine diseases, and it partners with pharma and biotech companies to advance cell therapies to the clinic.

11 investors

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors. Its lead focus is treating choroidal melanoma, a rare ocular cancer for which no first-line drug therapies currently exist.

11 investors

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain. It translates discoveries from Boston Children's Hospital, Harvard and Laval University into central nervous system therapies.

11 investors

BenchSci builds AI infrastructure for preclinical drug discovery, using machine learning that reads scientific literature to extract experimental evidence and map disease biology for biopharma R&D teams. Its tools help scientists select reagents and model systems and reason about targets, pathways, and mechanisms to reduce failed experiments.

11 investors

Biotia develops infectious disease diagnostics using clinical metagenomic next-generation sequencing paired with artificial intelligence, offering diagnostic tests and genomics software for patients, providers, and health systems managing challenging infections. Its products detect pathogens and antimicrobial resistance markers and support genomic surveillance and infection control.

11 investors

CatenaBio develops precision conjugation technology using native amino acids to enable biotherapeutic fusions of small molecules, nucleic acids, enzymes, and cells. The company partners with pharmaceutical firms to advance development of novel therapeutic modalities.

11 investors

Chemify builds automated chemical synthesis systems combining chemistry, AI, and robotics to digitize molecular design and manufacturing. The company serves pharmaceutical, materials, and chemical discovery partners seeking faster and more scalable access to novel molecules and drugs.

11 investors